⌕
Prestige Consumer Healthcare · PBH · NYSE
Tenet 52 · Mixed
Compare
$48.00+3.92%At closeTenet 52 · Mixed
$48.00+1.81 (+3.92%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD

Prestige Consumer Healthcare (PBH) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● MarketBeatNov 8, 2026 · 09:14 ETEARNINGS EXPECTED BY FEB 5
What Premium Brands (PBH) Said on Its Q3 Earnings Call

Premium Brands TSE: PBH maintained its outlook and expressed confidence in its 2027 growth targets, even as weaker foodservice demand and a delayed procurement initiative at its Stampede business contributed to a third-q…

● MarketBeatNov 7, 2026 · 22:15 ETEARNINGS EXPECTED BY FEB 5
Prestige Consumer Healthcare Q2 Earnings Call Highlights

Prestige Consumer Healthcare NYSE: PBH reported fiscal second-quarter revenue growth of 22.7%, driven by its recent acquisitions, but lowered its full-year outlook as production disruptions continued to constrain its Cle…

● Seeking AlphaNov 7, 2026 · 18:24 ETEARNINGS EXPECTED BY FEB 5
Prestige Consumer Healthcare Inc. (PBH) Q2 2027 Earnings Call Transcript

Prestige Consumer Healthcare Inc. ( PBH ) Q2 2027 Earnings Call November 5, 2026 8:30 AM EST Company Participants Philip Terpolilli - Director of Investor Relations Ron Lombardi - Chairman, President & CEO Christine Sacc…

● Zacks Investment ResearchNov 5, 2026 · 10:31 ETEARNINGS EXPECTED BY FEB 5
Compared to Estimates, Prestige Consumer Healthcare (PBH) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Str…

● GlobeNewsWireNov 5, 2026 · 06:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 5
Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results

TARRYTOWN, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first half fiscal 2027 ended September 30, 2026.…

● Business WireNov 4, 2026 · 09:00 ET
Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts.…

● GuruFocusOct 23, 2026 · 19:59 ET
Prestige Consumer Healthcare Inc (PBH) Shares Fall 3.4% -- What GF Score of 70 Tells Investors

On October 23, 2026, Prestige Consumer Healthcare Inc (PBH) shares fell 3.4%, closing at $47.80. The stock has experienced significant volatility, with a 52-wee…

● Zacks Investment ResearchOct 15, 2026 · 11:26 ET
Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?

PBH's brand-building, acquisitions and e-commerce growth support fiscal 2027 revenue gains, but competition and currency risks remain key challenges.…

● GlobeNewsWireOct 14, 2026 · 08:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 5
Prestige Consumer Healthcare to Release Fiscal 2027 Second Quarter Earnings Results

TARRYTOWN, N.Y., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2027 second quarter and first half earnings release on Thursday, November 5, 2…

● MarketBeatOct 3, 2026 · 03:03 ET
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Applica…

● Zacks Investment ResearchOct 1, 2026 · 08:30 ET
Best Value Stocks to Buy for October 1st

BP and PBH made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 1, 2026.…

● Zacks Investment ResearchSep 30, 2026 · 12:41 ET
PBH vs. NEOG: Which Stock Is the Better Value Option?

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stock…

● Defense WorldSep 25, 2026 · 04:23 ET
Premium Brands (TSE:PBH) Reaches New 52-Week Low – Here’s What Happened

Premium Brands Holdings Co. (TSE: PBH - Get Free Report) hit a new 52-week low during trading on Wednesday. The company traded as low as C$75.25 and last traded at C$75.55, with a volume of 13629 shares changing hands. T…

● Zacks Investment ResearchSep 14, 2026 · 12:40 ET
PBH or NEOG: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?…

● Seeking AlphaSep 10, 2026 · 17:27 ET
Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript

Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript…

● GlobeNewsWireSep 8, 2026 · 17:00 ETCOMPANY'S OWN WORDS
Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference

TARRYTOWN, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that Ron Lombardi, Chairman, President, & CEO and Christine Sacco, CFO and COO will participate in a firesi…

● Zacks Investment ResearchAug 28, 2026 · 12:41 ET
PBH vs. SYK: Which Stock Is the Better Value Option?

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now…

● Fox BusinessAug 21, 2026 · 17:00 ET
Nearly 40,000 eye drops recalled nationwide over possible contamination

Prestige Brand Holdings is recalling 39,060 bottles of certain Clear Eyes drops over sterility concerns, according to a Food and Drug Administration report.…

● Seeking AlphaAug 18, 2026 · 13:08 ETEARNINGS EXPECTED BY FEB 5
Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts

Amylyx Pharmaceuticals, Inc. is upgraded to Strong Buy after positive phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia [PBH]. Avexitide met its primary endpoint, achieving a 55% reduction in severe h…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 5. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.